;for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid."/>
公开/公告号US2021196690A1
专利类型
公开/公告日2021-07-01
原文格式PDF
申请/专利权人 PANOPTICA INC.;
申请/专利号US202117199506
申请日2021-03-12
分类号A61K31/427;A61K9;A61K47/40;A61K9/08;A61K47/18;
国家 US
入库时间 2022-08-24 19:43:08